VRDNViridian Therapeutics, Inc.
$18.67-3.9% 1Y
$18.67
$13.3052 weeks$33.78
Is the price fair?
What VRDN's price assumes
Viridian Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 27.1× revenue.
27.1
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.66
Price / book · today's price, fiscal year to Dec 31, 2025
- EV / sales
- 17.8
EV / sales
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 2.66
- EV / EBIToperating margin −570%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 17.8
- Market capitalisation
- $1.92B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks